Article in Bioprocess International. Vol 15, Issue 3, March 2017

March 22, 2017 Article in Bioprocess International. Vol 15, Issue 3, March 2017

“Drivers, Opportunities, and Limits of Continuous Processing”

Biologics represent a significant group of approved drugs, and they are expected to continue their exceptional growth in the foreseeable future. At first glance, innovative monoclonal antibodies (MAbs) and their derivatives seem to dominate the field; however, biobetters, biosimilars, and other therapeutic proteins have gained in relevance lately. This diverse portfolio also is reflected in the range of different biomanufacturing processes used. Most blockbuster antibodies are produced by mammalian cells cultured in large bioreactors (10-20 m³) in fed-batch mode.

You will find our article here.

Contact Person:
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication
communications@rentschler-biopharma.com